Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.
Latest Information Update: 17 Sep 2021
Price :
$35 *
At a glance
- Drugs Interleukin-2 (Primary) ; MVA 5T4 (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Oxford BioMedica
- 10 Nov 2008 New source identified and integrated (Current Controlled Trials record ISRCTN83977250)
- 31 Jul 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Jun 2008 Results presented at American Society of Clinical Oncology (ASCO) annual meeting in 2008.